Stock Track | Axsome Therapeutics Soars 5.03% Intraday on Strong Q1 Revenue Growth, FDA Approval and Analyst Upgrades

Stock Track05-04

Axsome Therapeutics' stock surged 5.03% during Monday's trading session, driven by the company's robust first-quarter financial results and positive business developments.

The biopharmaceutical company reported Q1 2026 net product revenue of $191.2 million, representing a 57% year-over-year increase. This growth was primarily fueled by a 59% rise in sales of AUVELITY, which reached $153.2 million. The strong performance comes alongside the recent FDA approval of AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease, with a full commercial launch scheduled for June 2026.

Multiple analyst firms responded positively to the earnings report, raising their price targets on Axsome Therapeutics. Deutsche Bank increased its target to $281 from $245 while maintaining a Buy rating, H.C. Wainwright raised its target to $270 from $250, and Needham lifted its target to $255 from $225. These upgrades reflect optimism about the company's growth trajectory and pipeline prospects despite a widening net loss due to increased commercialization expenses.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116750640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116750640","market":"us","top_or_hot":-1,"title":"Stock Track | Axsome Therapeutics Soars 5.03% Intraday on Strong Q1 Revenue Growth, FDA Approval and Analyst Upgrades","media":"Stock Track","content":"<p>Axsome Therapeutics' stock surged 5.03% during Monday's trading session, driven by the company's robust first-quarter financial results and positive business developments.</p><p>The biopharmaceutical company reported Q1 2026 net product revenue of $191.2 million, representing a 57% year-over-year increase. This growth was primarily fueled by a 59% rise in sales of AUVELITY, which reached $153.2 million. The strong performance comes alongside the recent FDA approval of AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease, with a full commercial launch scheduled for June 2026.</p><p>Multiple analyst firms responded positively to the earnings report, raising their price targets on Axsome Therapeutics. Deutsche Bank increased its target to $281 from $245 while maintaining a Buy rating, H.C. Wainwright raised its target to $270 from $250, and Needham lifted its target to $255 from $225. These upgrades reflect optimism about the company's growth trajectory and pipeline prospects despite a widening net loss due to increased commercialization expenses.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Axsome Therapeutics Soars 5.03% Intraday on Strong Q1 Revenue Growth, FDA Approval and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Axsome Therapeutics Soars 5.03% Intraday on Strong Q1 Revenue Growth, FDA Approval and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-04 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Axsome Therapeutics' stock surged 5.03% during Monday's trading session, driven by the company's robust first-quarter financial results and positive business developments.</p><p>The biopharmaceutical company reported Q1 2026 net product revenue of $191.2 million, representing a 57% year-over-year increase. This growth was primarily fueled by a 59% rise in sales of AUVELITY, which reached $153.2 million. The strong performance comes alongside the recent FDA approval of AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease, with a full commercial launch scheduled for June 2026.</p><p>Multiple analyst firms responded positively to the earnings report, raising their price targets on Axsome Therapeutics. Deutsche Bank increased its target to $281 from $245 while maintaining a Buy rating, H.C. Wainwright raised its target to $270 from $250, and Needham lifted its target to $255 from $225. These upgrades reflect optimism about the company's growth trajectory and pipeline prospects despite a widening net loss due to increased commercialization expenses.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1116750640","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116750640","pubTimestamp":1777901629,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Axsome Therapeutics' stock surged 5.03% during Monday's trading session, driven by the company's robust first-quarter financial results and positive business developments.The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"translate_title":"个股追踪|Axsome Therapeutics盘中大涨5.03%，因Q1营收强劲增长、FDA批准和分析师上调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":1},"content_text":"Axsome Therapeutics' stock surged 5.03% during Monday's trading session, driven by the company's robust first-quarter financial results and positive business developments.The biopharmaceutical company reported Q1 2026 net product revenue of $191.2 million, representing a 57% year-over-year increase. This growth was primarily fueled by a 59% rise in sales of AUVELITY, which reached $153.2 million. The strong performance comes alongside the recent FDA approval of AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease, with a full commercial launch scheduled for June 2026.Multiple analyst firms responded positively to the earnings report, raising their price targets on Axsome Therapeutics. Deutsche Bank increased its target to $281 from $245 while maintaining a Buy rating, H.C. Wainwright raised its target to $270 from $250, and Needham lifted its target to $255 from $225. These upgrades reflect optimism about the company's growth trajectory and pipeline prospects despite a widening net loss due to increased commercialization expenses.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116750640","isCrawlerRequest":true}